TNXP Archives - BioTuesdays

Developments

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...

September 5, 2023

Developments

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix Pharmaceuticals (NASDAQ:TNXP) agreed to acquire two currently-marketed products from Upsher-Smith Laboratories: Zembrace SymTouch injection 3 mg, and Tosymra nasal spray 10 mg, for the treatment of acute migraine...

June 26, 2023

Developments

Tonix expedites fibromyalgia and chronic migraine programs

Tonix Pharmaceuticals (NASDAQ:TNXP) is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia and its Phase 2 PREVENTION study of TNX-1900 for...

April 13, 2023

Developments

Tonix presents positive Phase 3 data in fibromyalgia

Tonix Pharmaceuticals (NASDAQ:TNXP) presented a poster at the 5th International Congress on Controversies in Fibromyalgia in Vienna that its TNX-102 SL met its pre-specified primary endpoint in the Phase 3 RELIEF trial...

March 30, 2023

Developments

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...

February 6, 2023

Developments

FDA clears Tonix IND in major depressive disorder

The FDA approved Tonix Pharmaceuticals’ (NASDAQ:TNXP) IND application to support a Phase 2 clinical trial with TNX-601 ER, a once-daily formulation of tianeptine as a potential treatment for major depressive disorder...

October 3, 2022

Developments

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVAIL study of TNX-102 SL as a potential treatment for a subset of patients with Long COVID syndrome whose symptoms overlap with...

August 22, 2022

Markets

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...

July 28, 2022

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Developments

Tonix Pharma TNX-1500 data presented at American Transplant Congress

Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in...

June 9, 2022

Tag - TNXP

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix expedites fibromyalgia and chronic migraine programs

Tonix presents positive Phase 3 data in fibromyalgia

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

FDA clears Tonix IND in major depressive disorder

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharma TNX-1500 data presented at American Transplant Congress

General

More